Дискуссионные проблемы потенциального вреда применения ингибиторов протонного насоса
Аннотация
В статье обсуждаются данные о высокой частоте назначения ингибиторов протонного насоса без показаний и о проявлениях потенциального вреда их применения.
Об авторах
Ю. В. Муравьев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522, Москва, Каширское шоссе, 34А
О. Р. Бобкова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А
Конфликт интересов:
Россия
115522, Москва, Каширское шоссе, 34А
Конфликт интересов:
34A, Kashirskoe Shosse, Moscow 115522
Список литературы
1. Федеральное руководство по использованию лекарственных средств (формулярная система). Выпуск XV. Москва: Эхо; 2014. 1020 с. [Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) [Federal Guidelines for the Use of Medicines (Formulary System)]. Vol. XV. Moscow: Ekho;2014. 1020 p. (In Russ.)].
2. Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleve Clin J Med. 2011;78(1):39-49. doi: 10.3949/ccjm.77a.10087
3. Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med. 2010;170(9):747-8. doi: 10.1001/archinternmed.2010.64
4. U.S. Food and Drug Administration (FDA). FDA Drug Safety Podcast for Healthcare Professionals:Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). Available: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm245455.htm, 2009.
5. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25:333-40. doi: 10.1046/j.1365-2710.2000.00312.x
6. Mat Saad AZ, Collins N, Lobo MM, O'Connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59:31-4. doi: 10.1111/j.1742-1241.2004.00298.x
7. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci. 2001;23:116-7.doi: 10.1023/A:1011278030001
8. Grant K, Al-Adhami N, Tordoff J, et al. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28:189-93. doi: 10.1007/s11096-006-9028-4
9. Pham CQD, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother. 2006;40:1261-6. doi: 10.1345/aph.1G703
10. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2-3. doi: 10.1136/bmj.39406.449456.BE
11. Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101:445-8. doi: 10.1093/qjmed/hcn035
12. Zink DA, Pohlman M, Barnes M, et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21:1203-9. doi: 10.1111/j.1365-2036.2005.02454.x
13. Strid H, Simren M, Bjornsson ES. Overuse of acid suppressant drugs in patients with chronic renal failure. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association. Nephrol Dial Transplant. 2003;18:570-5. doi: 10.1093/ndt/18.3.570
14. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867-78. doi: 10.1001/jama.2008.892
15. Grady D, Redberg RF. Less is more: how less health care can result in better health. Arch Intern Med. 2010;170:749-50. doi: 10.1001/archinternmed.2010.90
16. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834-6. doi: 10.1056/NEJMc066308
17. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37(7):1237-41. doi: 10.3109/0886022X.2015.1057800
18. Semb S, Helgstrand F, Hjorne F, Bytzer P Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication. World J Gastroenterol. 2017;23(37):6907-10. doi: 10.3748/wjg.v23.i37.6907
19. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435-42. doi: 10.1001/jama.2013.280490
20. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483-90. doi: 10.1016/j.cgh.2012.12.011
21. Wang L, Li M, Cao Y, at al. Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System. Sci Rep. 2017;7(1):5527. doi: 10.1038/s41598-017-05552-1
22. Zhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339-47. doi: 10.1007/s00198-015-3365-x
23. O'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778-81. doi: 10.1016/j.amjmed.2005.02.007
24. Targownik LE, Leslie WD, Davison KS, et al; CaMos Research Group. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107(9):1361-9. doi: 10.1038/ajg.2012.200
25. Targownik LE, Goertzen AL, Luo Y, Leslie WD. Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol. 2017;112(1):95-101. doi: 10.1038/ajg.2016.481
26. Freedberg DE, Kim LS, Yang YX. The risks and benefits of longterm use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706-15. doi: 10.1053/j.gastro.2017.01.031
27. Kwok CS, Arthur AK, Anibueze CI, at al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: metaanalysis. Am J Gastroenterol. 2012;107(7):1011-9. doi: 10.1038/ajg.2012.108
28. Freedberg DE, Toussaint NC, Chen SP, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883-885.e9. doi: 10.1053/j.gastro.2015.06.043
29. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001-10. doi: 10.1038/ajg.2012.179
30. Tariq R, Singh S, Gupta A, at al. Association of gastric acid suppression with recurrent Clostridium difficile infection:a systematic review and meta-analysis. JAMA Intern Med. 2017;177(6):784-91. doi: 10.1001/jamainternmed.2017.0212
31. Khanna S, Aronson SL, Kammer PP, еt al. Gastric acid suppression and outcomes in Clostridium difficile infection: a populationbased study. Mayo Clin Proc. 2012;87(7):636-42. doi: 10.1016/j.mayocp.2011.12.021
32. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238-46. doi: 10.1001/jamainternmed.2015.7193
33. Xie Y, Bowe B, Li T, et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153-63. doi: 10.1681/ASN.2015121377
34. Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a populationbased cohort study. CMAJ Open. 2015;3(2):E166-E171. doi: 10.9778/cmajo.20140074
35. Klatte DCF, Gasparini A, Xu H, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153(3):702-10. doi: 10.1053/j.gastro.2017.05.046
36. International Society of Nephrology. Summary of recommendation statements. Kidney Int Suppl. 2013;3(1):5-14. doi: 10.1038/kisup.2012.77
37. Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265(5):419-28. doi: 10.1007/s00406-014-0554-0
38. Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410-6. doi: 10.1001/jamaneurol.2015.4791
39. Taipale H, Tolppanen AM, Tiihonen M, et al. No association between proton pump inhibitor use and risk of Alzheimer's disease [pub. online ahead of print July 11, 2017]. Am J Gastroenterol. doi: 10.1038/ajg.2017.196
40. Badiola N, Alcalde V, Pujol A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8(3):e58837. doi: 10.1371/journal.pone.0058837
41. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955-60. doi: 10.1001/jama.292.16.1955
42. Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310-9. doi: 10.1503/cmaj.092129
43. Xie Y, Bowe B, Li T, et al. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7(6):e015735. doi: 10.1136/bmjopen-2016-015735
44. Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-39. doi: 10.1016/S0140-6736(96)09457-3
45. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associatedwith concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-44. doi: 10.1001/jama.2009.261
46. Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.
47. Circulation. 2011;123(5):474-82. doi: 10.1161/CIRCULATIONAHA.110.965640
48. Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153(6):378-86. doi: 10.7326/0003-4819-153-6-201009210-00005
49. Douglas IJ, Evans SJ, Hingorani AD, et al. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ. 2012;345:e4388. doi: 10.1136/bmj.e4388
50. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989-97. doi: 10.1016/S0140-6736(09)61525-7
51. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-17. doi: 10.1056/NEJMoa1007964
52. Holmes DR, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010;56(4):321-41. doi: 10.1016/j.jacc.2010.05.013
53. Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690. doi: 10.1136/bmj.d2690
54. Goodman SG, Clare R, Pieper KS, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012;125(8):978-86. doi: 10.1161/CIRCULATIONAHA.111.032912
55. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One. 2015;10(6):e0124653.doi: 10.1371/journal.pone.0124653
56. Otani IM, Banerji A. Immediate and Delayed Hypersensitivity Reactions to Proton Pump Inhibitors: Evaluation and Management. Curr Allergy Asthma Rep. 2016;16(3):17. doi: 10.1007/s11882-016-0595-8
57. Lin CY, Wang CW, Hui CR, et al. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T-cell reactivity study. Allergy. 2018;73(1):221-9. doi: 10.1111/all.13235
58. Correia O, Viana H, Azevedo R, et al. Possible phototoxicity with subsequent progression to discoid lupus following pantoprazole administration. Clin Exp Dermatol. 2001;26:455-6. doi: 10.1046/j.1365-2230.2001.00857.x
59. Dam C, Bygum A. Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors. Acta Derm Venereol. 2008;88:87-9. doi: 10.2340/00015555-0335
60. Bracke A, Nijsten T, Vandermaesen J, et al. Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases. Acta Derm Venereol. 2005;1:1. doi: 10.1080/00015550510026668
61. Panting K, Pinto M, Ellison J. Lansoprazole-induced subacute cutaneous lupus erythematosus. Clin Exp Dermatol. 2009;34:733-4. doi: 10.1111/j.1365-2230.2008.03105.x
62. Mankia SK, Rytina E, Burrows NP. Omeprazole-induced subacute cutaneous lupus erythematosus. Clin Exp Dermatol Wiley. 2010;35:e1-2. doi: 10.1111/j.1365-2230.2008.03125.x
63. Toms-Whittle L, John L, Buckley D. Drug-induced subacute cutaneous lupus erythematosus associated with omeprazole. Clin Exp Dermatol. 2011;36:281-3. doi: 10.1111/j.1365-2230.2010.03926.x
64. Wee J, Natkunarajah J, Marsden R. A difficult diagnosis: druginduced subacute cutaneous lupus erythematosus (SCLE) triggered by omeprazole in a patient with pre-existing idiopathic SCLE. Clin Exp Dermatol. 2012;37:445-6. doi: 10.1111/j.1365-2230.2011.04245.x
65. McCourt C, Somerville J, McKenna K. Anti-Ro and anti-La antibody positive subacute cutaneous lupus erythematosus (SCLE) induced by lansoprazole. Eur J Dermatol. 2010;20:860-1.
66. Almebayadh M, Regnier-Rosencher E, Carlotti A, et al. Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors. Dermatology. 2013;226:119-23. doi: 10.1159/000346694
67. Alcantara-Gonzalez J, Truchuelo-DТez MT, Gonzalez-Garcia C, Jaen Olasolo P. [Esomeprazole-induced subacute cutaneous lupus erythematosus]. Actas Dermosifil. 2011;102:638-40. doi: 10.1016/j.ad.2010.09.018
Для цитирования:
Муравьев Ю.В., Бобкова О.Р. Дискуссионные проблемы потенциального вреда применения ингибиторов протонного насоса. Научно-практическая ревматология. 2018;56(5):671-674. https://doi.org/10.14412/1995-4484-2018-671-674
For citation:
Muravyev Yu.V., Bobkova O.R. POTENTIAL HARMS OF THE USE OF PROTON PUMP INHIBITORS: DEBATABLE PROBLEMS. Rheumatology Science and Practice. 2018;56(5):671-674. (In Russ.) https://doi.org/10.14412/1995-4484-2018-671-674
Просмотров: 264
Послать статью по эл. почте 
